Building Small Molecule Drugs that Are Superior to Biologics
The Bio Report
00:00
Mitmy Seron, What's It About Your Approach That Gives You Confidence?
We have a great, you know, drug discovery team with great small molecule drug hunters. And our cost of target to i and d is less than half the industry average. We don't like to take risks in biology. There's just a lot of opportunity to convert these biologics into small molecules so that they can be more accessible to all but also be best in class medicines.
Transcript
Play full episode
